Compared to anti-gp210-negative individuals, anti-gp210-positive PBC patients had worse prognoses, higher levels of biochemical liver tests, more severe histological presentations, and worse responses to ursodeoxycholic acid (UDCA) (39.3% vs. 16.7%) [62]. The gene discussed is NUP210; the disease is primary biliary cholangitis.